These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 17124593)

  • 1. Dexamethasone as a probe for CYP3A4 metabolism: evidence of gender effect.
    Puisset F; Chatelut E; Sparreboom A; Delord JP; Berchery D; Lochon I; Lafont T; Roché H
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):305-8. PubMed ID: 17124593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dexamethasone as a probe for docetaxel clearance.
    Puisset F; Chatelut E; Dalenc F; Busi F; Cresteil T; Azéma J; Poublanc M; Hennebelle I; Lafont T; Chevreau C; Roché H
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):265-72. PubMed ID: 15133628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C(14)-erythromycin breath test and the antipyrine clearance test.
    Michael M; Cullinane C; Hatzimihalis A; O'Kane C; Milner A; Booth R; Schlicht S; Clarke SJ; Francis P
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):125-35. PubMed ID: 21626050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance.
    Hirth J; Watkins PB; Strawderman M; Schott A; Bruno R; Baker LH
    Clin Cancer Res; 2000 Apr; 6(4):1255-8. PubMed ID: 10778948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of advanced age and serum α
    Kenmotsu H; Imamura CK; Ono A; Omori S; Nakashima K; Wakuda K; Taira T; Naito T; Murakami H; Takahashi T; Tanigawara Y
    Br J Clin Pharmacol; 2017 Nov; 83(11):2416-2425. PubMed ID: 28640540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol.
    Yamamoto N; Tamura T; Kamiya Y; Sekine I; Kunitoh H; Saijo N
    J Clin Oncol; 2000 Jun; 18(11):2301-8. PubMed ID: 10829051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of weekly docetaxel in patients with advanced cancer.
    Slaviero KA; Clarke SJ; McLachlan AJ; Blair EY; Rivory LP
    Br J Clin Pharmacol; 2004 Jan; 57(1):44-53. PubMed ID: 14678339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of association of single-nucleotide polymorphisms in pregnane X receptor, hepatic nuclear factor 4alpha, and constitutive androstane receptor with docetaxel pharmacokinetics.
    Tham LS; Holford NH; Hor SY; Tan T; Wang L; Lim RC; Lee HS; Lee SC; Goh BC
    Clin Cancer Res; 2007 Dec; 13(23):7126-32. PubMed ID: 18056193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies.
    Goh BC; Lee SC; Wang LZ; Fan L; Guo JY; Lamba J; Schuetz E; Lim R; Lim HL; Ong AB; Lee HS
    J Clin Oncol; 2002 Sep; 20(17):3683-90. PubMed ID: 12202670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of systemic exposure to unbound docetaxel and neutropenia.
    Baker SD; Li J; ten Tije AJ; Figg WD; Graveland W; Verweij J; Sparreboom A
    Clin Pharmacol Ther; 2005 Jan; 77(1):43-53. PubMed ID: 15637530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol.
    Yamamoto N; Tamura T; Murakami H; Shimoyama T; Nokihara H; Ueda Y; Sekine I; Kunitoh H; Ohe Y; Kodama T; Shimizu M; Nishio K; Ishizuka N; Saijo N
    J Clin Oncol; 2005 Feb; 23(6):1061-9. PubMed ID: 15657405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers.
    Yong WP; Wang LZ; Tham LS; Wong CI; Lee SC; Soo R; Sukri N; Lee HS; Goh BC
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):243-51. PubMed ID: 17909805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel.
    Cox MC; Low J; Lee J; Walshe J; Denduluri N; Berman A; Permenter MG; Petros WP; Price DK; Figg WD; Sparreboom A; Swain SM
    Clin Cancer Res; 2006 Aug; 12(15):4636-40. PubMed ID: 16899612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel.
    Engels FK; Ten Tije AJ; Baker SD; Lee CK; Loos WJ; Vulto AG; Verweij J; Sparreboom A
    Clin Pharmacol Ther; 2004 May; 75(5):448-54. PubMed ID: 15116057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of protein-unbound docetaxel in cancer patients.
    Minami H; Kawada K; Sasaki Y; Igarashi T; Saeki T; Tahara M; Itoh K; Fujii H
    Cancer Sci; 2006 Mar; 97(3):235-41. PubMed ID: 16542221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes.
    de Graan AJ; Sparreboom A; de Bruijn P; de Jonge E; van der Holt B; Wiemer EA; Verweij J; Mathijssen RH; van Schaik RH
    Br J Clin Pharmacol; 2015 Sep; 80(3):560-8. PubMed ID: 26119961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dexamethasone as a probe for vinorelbine clearance.
    Puisset F; Dalenc F; Chatelut E; Cresteil T; Lochon I; Tisnes P; Roché H
    Br J Clin Pharmacol; 2005 Jul; 60(1):45-53. PubMed ID: 15963093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A clinical pharmacokinetic microdosing study of docetaxel with Japanese patients with cancer.
    Fujita K; Yoshino E; Kawara K; Maeda K; Kusuhara H; Sugiyama Y; Yokoyama T; Kaneta T; Ishida H; Sasaki Y
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):793-801. PubMed ID: 26297058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
    Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
    Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms.
    Tran A; Jullien V; Alexandre J; Rey E; Rabillon F; Girre V; Dieras V; Pons G; Goldwasser F; Tréluyer JM
    Clin Pharmacol Ther; 2006 Jun; 79(6):570-80. PubMed ID: 16765145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.